OTCMKTS:XSNX NovAccess Global (XSNX) Stock Price, News & Analysis $0.0003 0.00 (0.00%) As of 06/27/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartSEC FilingsShort InterestBuy This Stock About NovAccess Global Stock (OTCMKTS:XSNX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get NovAccess Global alerts:Sign Up Key Stats Today's Range$0.0003▼$0.000350-Day Range N/A52-Week Range$0.0001▼$0.0190VolumeN/AAverage Volume5,224 shsMarket Capitalization$13.38 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewNovAccess Global Inc., a biopharmaceutical company, develops novel immunotherapies to treat brain tumor patients in the United States. It specializes in cutting-edge research related to utilizing a patient's immune system to attack the cancer. The company was incorporated in 1997 and is headquartered in Chagrin Falls, Ohio.Read More… Receive XSNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NovAccess Global and its competitors with MarketBeat's FREE daily newsletter. Email Address XSNX Stock News HeadlinesGlobal wage calculator: Compare your salaryNovember 14, 2024 | money.cnn.comNovAccess Global Inc.August 28, 2024 | wsj.comTrump’s unwinnable warOver the years, we’ve been dragged into a long line of wars. The war on drugs. The war on terror. Wars with no clear goal, no endgame… no real answers for why we were fighting them in the first place. Trillions spent, countless young lives lost, and what do we have to show for it? And now, as yet another conflict erupts in the Middle East and billions more are burned in foreign sand, I urge you: Do not be distracted. June 30 at 2:00 AM | Porter & Company (Ad)NovAccess Global Inc. (XSNX)July 21, 2024 | finance.yahoo.comNovAccess Global Files Patent with Cedars-Sinai to Advance its Brain Cancer Fighting Vaccine PlatformMay 21, 2024 | finance.yahoo.comNovAccess Global Inc.: NovAccess Global Advisory on Annual Meeting of ShareholdersMay 7, 2024 | finanznachrichten.deNovAccess Global Announces New License to Advance its Immunotherapy PlatformApril 30, 2024 | finance.yahoo.comNovAccess Global Faces Default and Uncertain Rescue DealFebruary 7, 2024 | msn.comSee More Headlines XSNX Stock Analysis - Frequently Asked Questions How have XSNX shares performed this year? NovAccess Global's stock was trading at $0.01 at the beginning of the year. Since then, XSNX stock has decreased by 97.0% and is now trading at $0.0003. View the best growth stocks for 2025 here. How do I buy shares of NovAccess Global? Shares of XSNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of NovAccess Global own? Based on aggregate information from My MarketBeat watchlists, some other companies that NovAccess Global investors own include Co-Diagnostics (CODX), iBio (IBIO), Onconova Therapeutics (ONTX), Tonix Pharmaceuticals (TNXP), T2 Biosystems (TTOO), Kopin (KOPN) and Adamis Pharmaceuticals (ADMP). Company Calendar Today6/30/2025Fiscal Year End9/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:XSNX CIK1039466 Webwww.xsunx.com Phone(213) 642-9268Fax949-266-5823Employees2Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.58) per share Price / Book0.00Miscellaneous Outstanding Shares44,600,000Free Float43,961,000Market Cap$13.38 thousand OptionableNot Optionable Beta3.32 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (OTCMKTS:XSNX) was last updated on 6/30/2025 by MarketBeat.com Staff From Our PartnersBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | Sponsored“Trump’s 24-Hour Profit Windows” revealedTrading legend Larry Benedict has discovered a repeating surge of $240 billion (and more)... Flowing into a...Brownstone Research | Sponsored379 passengers walked away from thisElon Musk just wrote a $51 million check to back this material’s next phase… Because it’s not just saving l...True Market Insiders | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NovAccess Global Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NovAccess Global With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
